Mar 2, 2017 4:05 pm EST SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request
Jan 26, 2017 9:05 am EST SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors
Dec 13, 2016 8:00 am EST SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections
Dec 12, 2016 11:29 am EST SCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference
Nov 7, 2016 4:30 pm EST SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides Company Update
Oct 25, 2016 9:05 am EDT SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078
Oct 5, 2016 4:15 pm EDT SCYNEXIS Announces Complete Results from Two Phase 2 Studies of Oral SCY-078 in Patients with Candida spp. Infections and Closing of a $15 Million Term Loan
